Scientific Events Manager at MabDesign, I lead high-impact bioprocessing events, working with leading industry and academic stakeholders across Europe, and offering a front-row view of trends and innovations in biopharma manufacturing.
MabDesign provides scientific, technological, and business expertise in biotherapies and bioprocessing, for the benefit of drug developers as well as service providers. Founded in 2014, self-financed and strong of over 380 French and European members, the MabDesign association is committed to being the leading expert resource for stakeholders in this highly innovative field. With this aim, our science-oriented team proposes conferences, trainings courses and publications to disseminate innovations, along with business services to support the marketing, business development and non-dilutive financing of your innovations. Visit our website www.mabdesign.fr/en/ to learn more about our activities !
Prior to joining MabDesign, I graduated from the University of Geneva where I obtained a PhD in Biology in 2017, specialized in molecular biology and infectious diseases. I carried on my academic career as a postdoctoral fellow at the MRC Laboratory of Molecular Biology of the University of Cambridge (UK), focused on innate immunity. Through my path, I have been actively interested in building bridges between stakeholders, notably through the coordination of scientific events.
MabDesign’s innovation financing team helps identify relevant funding calls, structure high-impact proposals, and navigate EU and national programs, leveraging strong scientific and economic expertise in biotherapies to secure public funding.
Mabdesign offers tailored business intelligence in the biologics and bioproduction sectors. We help companies build strategies and identify opportunities through expert competitive analysis, market segmentation, and strategic positioning.
Join the first Bioproduction Forum (June 2–3, Lausanne), co-organized by MabDesign and A3P. A focused event gathering 130+ experts to explore advances in mAbs, ADCs and biosimilars through conferences, workshops and networking opportunities.